[ad_1]

If you think tech stocks have it rough right now, sneak a peek at biotech stocks.
The sector is in the midst of its most severe correction ever. Although it’s healthy to see excess squeezed out of valuations, that’s no consolation to investors who bought in during the peak last year. And the worst of the correction could be ahead.
That may sound scary, but investors aren’t helpless. It helps to navigate volatility by focusing on fundamentals.
Here’s how a back-to-the-basics approach and a focus on companies’ cash runways — their ability to fund themselves — might help individual investors find stable biotech stocks for 2023 and beyond.
!function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()
{n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
;if(!f._fbq)f._fbq=n;
n.push=n;n.loaded=!0;n.version=’2.0′;n.queue=[];t=b.createElement(e);t.async=!0;
t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
document,’script’,’https://connect.facebook.net/en_US/fbevents.js’);
(function(){
fbq(‘init’, ‘135067773744716’);
fbq(‘track’, ‘PageView’);
var contentId = ‘ci02aaa06e10002500’;
if (contentId !== ”) {
fbq(‘track’, ‘ViewContent’, {content_ids: [contentId], content_type: ‘product’});
}
})();
The post 5 Biotechs With Cash Runways Into 2025 appeared first on HumanitasConnects.
Source link